3.97MMarket Cap-0.13P/E (TTM)
0.5460High0.4850Low283.96KVolume0.5400Open0.5220Pre Close143.71KTurnover3.52%Turnover RatioLossP/E (Static)8.19MShares6.180052wk High0.73P/B3.91MFloat Cap0.425052wk Low--Dividend TTM8.06MShs Float40500.0000Historical High--Div YieldTTM11.69%Amplitude0.4250Historical Low0.5060Avg Price1Lot Size
Quoin Pharmaceuticals Stock Forum
The company plans to use proceeds for general corporate purposes, including operating ex...
$Quoin Pharmaceuticals (QNRX.US)$
Quoin Pharmaceuticals Announces FDA Clearance to Initiate New QRX003 Netherton Syndrome Clinical Study
Thursday, 19th December at 8:00 am
• Groundbreaking ‘Whole Body' Study will be conducted by Dr. Amy Paller at Northwestern University
• Up to eight subjects will have QRX003 applied twice daily to greater than 80% of their body surface area over a 12-week period
• Study intended to generate data based on product use resembling potential real-world use
• ...
⚠️nfa
GlobeNewswire· 4 mins ago
Clinical Data from First Subject Dosed Twice Daily with QRX003 in Open Label Study Is Positive at Mid-point of TestingSignificant Improvement in Skin Appearance Observed in Pediatric Study after Only 12 Days of Dosing with QRX003
📊⚡️📊
No comment yet